Benchmarking Investigator Payments

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Benchmarking Investigator Payments” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=799327

ISR’s New Report Shows eDetailing Fills Void Left by Reduced Rep Presence in Europe

Informing the drug development and commercialization industry. Cary, N.C. – December 5, 2012 – Industry Standard Research (ISR) today launched a new market research report titled “Adoption and Use of eDetailing vs. In-person Detailing in Europe,” providing pharmaceutical manufacturers with new insights into how European physicians prefer to interact with drug makers. “Like in most … Continued

ISR’s Report Analyzes Investigator Payments across 11 Therapeutic Areas

Informing the pharmaceutical and biotech industry. Cary, N.C. – October 30, 2012 – Industry Standard Research (ISR) today announced the availability of their newest report, “Benchmarking Investigator Payments,” which analyzes the level of compensation investigative sites receive for participation in clinical studies. “Investigator payments can account for over 40% of total trial costs, so it … Continued

ISR’s Hepatitis C Market Analysis Shows a Deep Pipeline, Uncovers Lack of Internet Search Visibility for Current Therapies

Informing the pharmaceutical and biotech industry. Cary, N.C. – October 9, 2012 – Industry Standard Research (ISR) today announced the availability of their latest report, “Hepatitis C: Social Media, Search, and Market Analysis,” providing a product and pipeline analysis of the Hepatitis C market, as well as a never before seen in-depth social media and … Continued

ISR Reports: Sponsors Indicate a Shift Towards Central Labs in Emerging Markets, Asia

Informing the pharmaceutical and biotech industry. Cary, N.C. – October  2, 2012 – Industry Standard Research (ISR) today announced the availability of their newest clinical development trends report, “Central Lab Market Dynamics and Outsourcing Performance,” which provides an in-depth analysis of topics and trends having an impact on the market for central lab market in … Continued

ISR Reports: Covance Receives Top Ratings in Phase IV Benchmarking Study

Informing the pharmaceutical and biotech industry. Cary, N.C. – September  18, 2012 – Industry Standard Research (ISR) today announced the availability of their newest CRO Benchmarking report, 2012 CRO Quality Benchmarking – Phase IV Service Providers, which provides service quality profiles for 10 Phase IV CROs. “Covance received the highest marks across a number of … Continued

ISR Adds Biosimilar Recruitment to Growing Library of Biosimliar, Recruitment Reports

Informing the pharmaceutical and biotech industry Cary, N.C. – September 11, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled “Improving Patient Recruitment in Biosimilar Trials,” which examines patient and site recruitment in Biosimilar clinical trials. “Teva’s use of a Biologics License Application (BLA) for their regulatory submission and … Continued

Selection of Phase I Service Providers

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Selection of Phase I Service Providers” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Selection-of-Phase-I-Service-Providers/ArticleStandard/Article/detail/788581

Optimizing Investigator Fees

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Optimizing Investigator Fees” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Data+Analysis/Optimizing-Investigator-Fees/ArticleStandard/Article/detail/800011 I’m not sure if it’s just me, but we still have some work to do on the automatically generated e-mails. I’ve provided DETAILED and SPECIFIC instructions I’d like to see … Continued

Access to patient population more important than price for Phase I outsourcing, says ISR

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Access to patient population more important than price for Phase I outsourcing, says ISR” https://www.outsourcing-pharma.com/Clinical-Development/Access-to-patient-population-more-important-than-price-for-Phase-I-outsourcing-says-ISR

Strong Link Between CRO Service Quality and Financial Performance

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Strong Link Between CRO Service Quality and Financial Performance” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=783320

ISR Reports: PPD Receives Top Marks for Customer Loyalty and Value in Phase I

Informing the drug development and commercialization industry Cary, N.C. – July  19, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled 2012 CRO Quality Benchmarking – Phase I Service Providers, which provides service quality profiles for 12 Phase I CROs. “PPD received higher ratings than any other Phase I … Continued

ISR’s Report Provides Novel Data for Oncology MSL and Sales Strategies

Informing the drug development and commercialization industry Cary, N.C. – June 18, 2012 – Industry Standard Research (ISR) today announced the launch of a new market research report titled “MSL and Sales Strategies for the US Oncology Market”, which provides the pharmaceutical and biotech sales and marketing professionals with insight into how US Oncologists want … Continued

ISR’s New Report Uncovers Barriers and Strategies in Investigator Recruitment

Informing the drug development and commercialization industry Cary, N.C. – May 23, 2012 – Industry Standard Research (ISR) today announced the launch of a new market research report titled “Optimizing Investigator Recruitment in Clinical Trials” that provides recruitment professionals with a resource to optimize investigator recruitment and mitigate study delays. ISR’s new report is based … Continued

ISR Profiles the State of Patient Recruitment in Clinical Trials

Informing the drug development and commercialization industry Cary, N.C. – May 2, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled “Optimizing Patient Recruitment in Clinical Trials” that provides sponsors and service providers with valuable insight into the activities and strategies that drive and restrict patient recruitment in clinical … Continued

ISR Study Finds That INC Research Delivers CRO Industry’s Most Consistent Service Quality

Informing the drug development and commercialization industry Cary, N.C. – February 28, 2012 – Industry Standard Research (ISR) today announced the availability of its 4th annual CRO Quality Benchmarking Report.  The 2012 version released Tuesday includes 125 pharmaceutical and biotechnology professionals and their experiences with dozens of small, mid-size, and large CROs offering Phase II/III … Continued

ISR Report Measures Impact of Sunshine Act on Physician, Drug Manufacturer Interactions

Informing the drug development and commercialization industry Cary, N.C. – February 26, 2012 – Industry Standard Research (ISR) today announced the release of a new pharmaceutical market research report entitled “Sunshine Act: Pharma Impact – Changes in US Physician Behavior,” which quantifies the impact the adoption of the Sunshine Act will have on physicians’ interactions … Continued

ISR Expands Biosimilar Library with Two New Reports

Informing the Drug Development and Commercialization Industry Cary, N.C. – January 31, 2012 – Industry Standard Research (ISR) today announced the release of two new reports focused on the biosimilar industry. “US Payers and Biosimilar Formulary Placement” and “Biosimilars: A View from the Pharmacy” expand the base of knowledge regarding biosimilar market dynamics.  These reports … Continued

ISR: US Payers Indicate Comparative Effectiveness Research Gaining Importance

Informing the Drug Development and Commercialization Industry Cary, N.C. – January 17, 2012 – Industry Standard Research (ISR) today announced the release of a new report focused on the impact comparative effectiveness research (CER) is and will have on formulary placement . “US Payers: Comparative Effectiveness Research and formulary decision-making” looks at how US payers … Continued

New ISR Research Shows Some Prescribers Want More – Not Less – Drug Detailing

Cary, N.C. – January 11, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled”Electronic vs. In-person Detailing: A head-to-head comparison of Volume, Time, Value and Outcomes” that captures and compares product detail experiences from 118 Cardiologists, Oncologists, Family Practitioners, and Allergy / Immunologists. “The commonly held wisdom from both … Continued

New ISR Report Indicates Sponsors Prefer Specialty Providers for Imaging Services

Cary, N.C. – January 4, 2012 – Industry Standard Research (ISR) today announced the release of a new report titled “Clinical Imaging Market Dynamics and Service Provider Performance” in which 36 pharmaceutical sponsor decision-makers provide their usage, insights, and forecasts regarding the clinical imaging market by rating 98 service provider encounters. “The clinical imaging market … Continued

ISR CUSTOMERS